CDK9 Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

CDK9 Specific Inhibitors

Product Name	CDK9	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK8	CDK12	CDK13	CDK14	CDK16	CDK19	CDK9 Selectivity	Purity
AZD4573	CDK9, IC₅₀: 4 nM														Selective Inhibitor	99.90%
NVP-2	CDK9, IC₅₀: 0.5 nM														Selective Inhibitor	≥98.0%
(+)-BAY-1251152	CDK9/CycT1, IC₅₀: 3 nM														Selective Inhibitor	99.66%
KB-0742 dihydrochloride	CDK9/cyclinT1, IC₅₀: 6 nM														Selective Inhibitor	99.63%
LDC000067	CDK9- Cyclin T1, IC₅₀: 44 nM	cdk1-cyclin B1, IC₅₀: 5513 nM	cdk2-cyclin A, IC₅₀: 2441 nM		cdk4-cyclin D1, IC₅₀: 9242 nM										Selective Inhibitor	98.58%
PHA-767491 hydrochloride	CDK9, IC₅₀: 34 nM	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM									Selective Inhibitor	99.91%
Atuveciclib	CDK9/CycT1, IC₅₀: 13 nM CDK9/CycT1(h), IC₅₀: 6 nM	CDK1/CycB(h), IC₅₀: 1100 nM	CDK2/CycE(h), IC₅₀: 1000 nM	CDK3/CycE(h), IC₅₀: 890 nM		CDK5/p35(h), IC₅₀: 1600 nM									Selective Inhibitor	99.20%
CDK9-IN-2	CDK9, IC₅₀: 5 nM (H929 multiple myeloma cell line)														Selective Inhibitor	99.84%
CDK12-IN-E9	CDK9/cyclinT1, IC₅₀: 23.9 nM		cdk2/cyclin A, IC₅₀: 932 nM					CDK7/Cyclin H/MNAT1, IC₅₀: 1210 nM							Selective Inhibitor	99.20%
CDK9-IN-1	CDK9/CycT1, IC₅₀: 39 nM														Selective Inhibitor	95.48%
PROTAC CDK9 Degrader-1	CDK9														Selective Inhibitor	98.34%
CDK-IN-2	CDK9/cyclinT1, IC₅₀: 8 nM														Selective Inhibitor	98.82%
MC180295	CDK9- Cyclin T1, IC₅₀: 5 nM	CDK1-Cyclin B, IC₅₀: 138 nM	cdk2-cyclin A, IC₅₀: 233 nM cdk2-cyclin E, IC₅₀: 367 nM	CDK3-Cyclin E, IC₅₀: 399 nM	CDK4-Cyclin D, IC₅₀: 112 nM	cdk5-p35, IC₅₀: 159 nM cdk5-p25, IC₅₀: 186 nM	cdk6-cyclin D3, IC₅₀: 712 nM	CDK7-CycH/MAT1, IC₅₀: 555 nM							Selective Inhibitor	98.47%
CDK9-IN-7	CDK9/cyclinT1, IC₅₀: 11 nM				CDK4/cyclin D, IC₅₀: 148 nM		CDK6/cyclinD, IC₅₀: 145 nM								Selective Inhibitor	99.81%
CDK9-IN-8	CDK9, IC₅₀: 12 nM														Selective Inhibitor	99.06%
JSH-150	CDK9/cyclinT1, IC₅₀: 1 nM	Cdk1/cyclin B, IC₅₀: 1.34 μM	cdk2/cyclin A, IC₅₀: 2.86 μM			Cdk5/p25, IC₅₀: 4.64 μM		CDK7/Cyclin H/MNAT1, IC₅₀: 1.72 μM				CDK14/Cyclin Y, IC₅₀: 1.68 μM	CDK16/Cyclin Y, IC₅₀: 292 nM		Selective Inhibitor	98.36%
CAN508	CDK9/cyclinT1, IC₅₀: 0.35 μM	Cdk1/cyclin B, IC₅₀: 44 μM	CDK2/cyclinE, IC₅₀: 20 μM cdk2/cyclin A, IC₅₀: 69 μM		Cdk4/cyclin D1, IC₅₀: 13.5 μM			CDK7/cyclin H, IC₅₀: 26 μM							Selective Inhibitor
FIT-039	CDK9/cyclinT1, IC₅₀: 5.8 μM														Selective Inhibitor	≥98.0%
PHA-767491	CDK9, IC₅₀: 34 nM	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM									Selective Inhibitor
CDK9-IN-9	CDK9, IC₅₀: 1.8 nM		CDK2, IC₅₀: 155 nM												Selective Inhibitor
CDK6/9-IN-1	CDK9, IC₅₀: 39.5 nM						CDK6, IC₅₀: 40.5 nM								Selective Inhibitor
CDK9-IN-11	CDK9														Selective Inhibitor
PROTAC CDK9 degrader-2	CDK9, IC₅₀: 17 μM (MCF-7 cells)														Selective Inhibitor
CDK9-IN-10	CDK9														Selective Inhibitor
Abemaciclib	CDK9/cyclinT1, IC₅₀: 57 nM	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	CDK5/p35, IC₅₀: 287 nM Cdk5/p25, IC₅₀: 355 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM							Pan Inhibitor	99.69%
Dinaciclib	CDK9, IC₅₀: 4 nM	CDK1, IC₅₀: 3 nM	CDK2, IC₅₀: 1 nM			CDK5, IC₅₀: 1 nM									Pan Inhibitor	99.36%
CDK7-IN-3	CDK9, Ki: 290 nM		CDK2, Ki: 390 nM					CDK7, Kd: 0.059 nM		CDK12, Ki: 78 nM					Pan Inhibitor
Abemaciclib methanesulfonate	CDK9/cyclinT1, IC₅₀: 57 nM	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	Cdk5/p25, IC₅₀: 355 nM CDK5/p35, IC₅₀: 287 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM							Pan Inhibitor	≥98.0%
THZ531	CDK9, IC₅₀: 10.5 μM							CDK7, IC₅₀: 8.5 μM		CDK12, IC₅₀: 158 nM	CDK13, IC₅₀: 69 nM				Pan Inhibitor	99.86%
CYC065	CDK9		CDK2												Pan Inhibitor	99.78%
SNS-032	CDK9, IC₅₀: 4 nM	CDK1, IC₅₀: 480 nM	CDK2, IC₅₀: 38 nM		CDK4, IC₅₀: 925 nM			CDK7, IC₅₀: 62 nM							Pan Inhibitor	98.50%
AZD-5438	cdk9-cyclin T, IC₅₀: 20 nM	cdk1-cyclin B1, IC₅₀: 16 nM	cdk2-cyclin E, IC₅₀: 6 nM cdk2-cyclin A, IC₅₀: 45 nM		cdk4-cyclin D1, IC₅₀: 449 nM	cdk5-p25, IC₅₀: 14 nM	cdk6-cyclin D3, IC₅₀: 21 nM	cdk7-cyclin H, IC₅₀: 821 nM							Pan Inhibitor	99.05%
AT7519	CDK9/Cyclin T, IC₅₀: 10 nM	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM							Pan Inhibitor	99.40%
Samuraciclib hydrochloride	CDK9/CycT1, IC₅₀: 1.2 μM	CDK1/cyc A, IC₅₀: 1.8 μM	cdk2/cyclin A, IC₅₀: 578 nM		CDK4/Cyc D1, IC₅₀: 49 μM	CDK5/p35NCK, IC₅₀: 9.4 μM	CDK6/cycD1, IC₅₀: 34 μM	CDK7/cyclin H, IC₅₀: 41 nM							Pan Inhibitor	99.98%
YKL-5-124 TFA	CDK9, IC₅₀: 3020 nM		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM							Pan Inhibitor	98.59%
CGP60474	CDK9/cycT, IC₅₀: 13 nM	CDK1-Cyclin B, IC₅₀: 26 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM		CDK4/cyclin D, IC₅₀: 216 nM	Cdk5/p25, IC₅₀: 10 nM		CDK7/cyclin H, IC₅₀: 200 nM							Pan Inhibitor	98.70%
(R)-CR8 trihydrochloride	CDK9/Cyclin T, IC₅₀: 0.18 μM	CDK1/cyclinB1, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM							Pan Inhibitor	99.02%
Roniciclib	CDK9/cyclinT1, IC₅₀: 5 nM	Cdk1/cyclin B, IC₅₀: 7 nM	CDK2/cyclinE, IC₅₀: 9 nM		CDK4/cyclin D, IC₅₀: 11 nM			CDK7/Cyclin H/MAT1, IC₅₀: 25 nM							Pan Inhibitor	98.89%
SEL120-34A monohydrochloride	CDK9/cycT, IC₅₀: 1070 nM								CDK8/CycC, IC₅₀: 4.4 nM					CDK19/CycC, IC₅₀: 10.4 nM	Pan Inhibitor	99.98%
THZ2	CDK9, IC₅₀: 194 nM	CDK1, IC₅₀: 96.9 nM	CDK2, IC₅₀: 222 nM			CDK5, IC₅₀: 134 nM		CDK7, IC₅₀: 13.9 nM	CDK8, IC₅₀: 6830 nM						Pan Inhibitor	≥95.0%
PHA-793887	CDK9/cyclinT1, IC₅₀: 138 nM	Cdk1/cyclin B, IC₅₀: 60 nM	cdk2/cyclin A, IC₅₀: 8 nM CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 62 nM	Cdk5/p25, IC₅₀: 5 nM		CDK7/cyclin H, IC₅₀: 10 nM							Pan Inhibitor	99.25%
LY2857785	CDK9, IC₅₀: 0.011 μM							CDK7, IC₅₀: 0.246 μM	CDK8, IC₅₀: 0.016 μM						Pan Inhibitor	98.88%
Riviciclib hydrochloride	CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.500 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM								Pan	98.33%
BS-181	CDK9/cycT, IC₅₀: 4.2 μM	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM							Pan Inhibitor	98.10%
BS-181 hydrochloride	CDK9/cycT, IC₅₀: 4.2 μM	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM							Pan Inhibitor	≥99.0%
CDKI-73	CDK9, IC₅₀: 5.78 nM CDK9, Ki: 4 nM	CDK1, IC₅₀: 8.17 nM CDK1, Ki: 4 nM	CDK2, IC₅₀: 3.27 nM CDK2, Ki: 3 nM		CDK4, IC₅₀: 8.18 nM		CDK6, IC₅₀: 37.68 nM	CDK7, IC₅₀: 134.26 nM CDK7, Ki: 91 nM							Pan Inhibitor	99.58%
Atuveciclib Racemate	CDK9														Pan Inhibitor	≥98.0%
AT7519 Hydrochloride	CDK9/Cyclin T, IC₅₀: 10 nM	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM							Pan Inhibitor	99.29%
Voruciclib hydrochloride	CDK9/CycT1, Ki: 1.68 nM CDK9/cyc T2, Ki: 0.626 nM	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM								Pan Inhibitor	98.20%
Lerociclib dihydrochloride	CDK9/Cyclin T, IC₅₀: 28 nM	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 832 nM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM							Pan Inhibitor	98.45%
(R)-CR8	CDK9/Cyclin T, IC₅₀: 0.18 μM	Cdk1/cyclin B, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM							Pan Inhibitor	≥98.0%
Voruciclib	CDK9/cyc T2, Ki: 0.626 nM CDK9/CycT1, Ki: 1.68 nM	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM								Pan Inhibitor	99.52%
SEL120-34A HCl	CDK9/cycT, IC₅₀: 1070 nM								CDK8/CycC, IC₅₀: 4.4 nM					CDK19/CycC, IC₅₀: 10.4 nM	Pan Inhibitor	99.98%
NVP-LCQ195	CDK9/cyclinT1, IC₅₀: 15 nM	Cdk1/cyclin B, IC₅₀: 2 nM	cdk2/cyclin A, IC₅₀: 2 nM CDK2/cyclinE, IC₅₀: 5 nM	CDK3/Cyclin E, IC₅₀: 42 nM		Cdk5/p25, IC₅₀: 1 nM CDK5/p35, IC₅₀: 1 nM	cdk6/cyclin D3, IC₅₀: 187 nM	CDK7/Cyclin H/MAT1, IC₅₀: 3564 nM							Pan Inhibitor	99.80%
TL12-186	CDK9/cyclinT1, IC₅₀: 55 nM		cdk2/cyclin A, IC₅₀: 73 nM												Pan Inhibitor	≥99.0%
PROTAC CDK2/9 Degrader-1	CDK9, DC₅₀: 33 nM		CDK2, DC₅₀: 62 nM												Pan Inhibitor	98.40%
SEL120-34A	CDK9/cycT, IC₅₀: 1070 nM								CDK8/CycC, IC₅₀: 4.4 nM					CDK19/CycC, IC₅₀: 10.4 nM	Pan Inhibitor
AT7519 trifluoroacetate	CDK9/Cyclin T, IC₅₀: 10 nM	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM							Pan Inhibitor	98.16%
CDK8/19-IN-1	CDK9, IC₅₀: 270 nM								CDK8/CycC, IC₅₀: 0.46 nM					CDK19/CycC, IC₅₀: 0.99 nM	Pan Inhibitor
IIIM-290	CDK9/T1, IC₅₀: 94 nM		CDK2/A, IC₅₀: 90 nM												Pan Inhibitor
Riviciclib	CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.540 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM								Pan Inhibitor
Lerociclib	CDK9/Cyclin T, IC₅₀: 28 nM	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 0.832 μM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM							Pan Inhibitor
BS-181 dihydrochloride	CDK9, IC₅₀: 4200 nM		CDK2, IC₅₀: 880 nM			CDK5, IC₅₀: 3000 nM		CDK7, IC₅₀: 21 nM							Pan Inhibitor
Bohemine	CDK9/cyclinT1, IC₅₀: 2.7 μM		CDK2/cyclinE, IC₅₀: 4.6 μM cdk2/cyclin A, IC₅₀: 83 μM												Pan Inhibitor	≥98.0%
YKL-5-124	CDK9, IC₅₀: 3020 nM		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM							Pan Inhibitor
(-)-BAY-1251152	CDK9														Inhibitor	99.82%
FN-1501-propionic acid	CDK9		CDK2

Name
Email *

	Sorry, but the email address you supplied was invalid.